GPC3 and hepatocellular carcinoma: More recently, Gao et al. [150] reported that HS20, a human monoclonal antibody against glypican-3, could inhibit hepatocellular carcinoma proliferation both in vitro and in nude mice by disrupting the interaction of Wnt3a and glypican-3 and blocking Wnt3a/β-catenin signaling.